Bolt Biotherapeutics, Inc.

This study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with multiple therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink t…

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…